SEC Form 4 · accession 0001179110-18-000486
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Katrine Bosley
Officer — President and CEO · Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 2, 2018 | S | 500 | $31.248 | D | 1,382,264 | D | |
| Common StockF3 | Jan 2, 2018 | S | 1,703 | $32.008 | D | 1,380,561 | D | |
| Common StockF4 | Jan 2, 2018 | S | 2,193 | $33.634 | D | 1,378,368 | D | |
| Common StockF5 | Jan 2, 2018 | S | 3,937 | $34.225 | D | 1,374,431 | D | |
| Common StockF6 | Jan 3, 2018 | S | 6,662 | $35.037 | D | 1,367,769 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $30.75 to $31.71. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $31.79 to $32.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $32.89 to $33.87. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $33.89 to $34.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $35 to $35.7. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.